Migration Biotherapeutics Ltd
We serve surgeons who operate on brain tumours in adults with a decoy nerve for Glioblastoma.
Problem
Glioblastoma is the most common primary brain tumour in adults. Median survival is around 14 months and no cure is available.
Solution
We are building a material acting as a ‘decoy-nerve’, directing the migration of brain tumour cells for therapeutic purposes.
Team
- Davide Danovi – Co-Founder & CSO
- Peter Bannister – Co-Founder & CEO
Website and social media
UN Sustainable Development Goals
